NCT02966509 (EPAC) is a NA clinical trial of EPAC in End of Life, sponsored by Stanford University.

Who is sponsoring NCT02966509?

NCT02966509 is sponsored by Stanford University.

What drugs are being tested in NCT02966509?

Interventions in NCT02966509: EPAC.

What condition does NCT02966509 study?

NCT02966509 studies End of Life, Advanced Cancer, Lung Neoplasm, Gastric Cancer, Colon Cancer, Glioblastoma Multiforme, Head and Neck Neoplasms, Rectum Cancer, Melanoma, Kidney Cancer, Prostate Cancer, Testicular Neoplasms, Liver Cancer, Cancer of Unknown Origin.

Is NCT02966509 still recruiting?

NCT02966509 is currently completed. Last updated 4 October 2018.

Are results published for NCT02966509?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-10-04 · How we verify

NCT02966509: EPAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Engagement of Patients With Advanced Cancer

Completed NA Results posted Last updated 4 October 2018

What this trial tests

NA trial testing EPAC in End of Life in 213 participants. Completed in 1 December 2016.

Timeline

1 August 2013

Primary endpoint
1 December 2016

1 December 2016

Quick facts

Lead sponsor	Stanford University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	213
Start date	1 August 2013
Primary completion	1 December 2016
Estimated completion	1 December 2016

Drugs / interventions tested

EPAC

Conditions studied

End of Life — all drugs for End of Life →
Advanced Cancer — all drugs for Advanced Cancer →
Lung Neoplasm — all drugs for Lung Neoplasm →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Stanford University

Who can join

18 and older, any sex, with End of Life or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled Medical Note Within 6 Months of Patient Enrollment in the Study.
Time frame: 6 months after each patient enrollment
Feasibility is defined as at least 75% of patients in the intervention arm with a documented Goals of Care titled medical note within 6 months of patient enrollment in the study.

Sponsor's own description

The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced cancer. Although lay health workers have never been tested in this role, we hypothesize that lay health workers can feasibly improve goals of care documentation and help to reduce unwanted healthcare utilization at the end of life for Veterans diagnosed with new advanced stages of cancer and those diagnosed with recurrent disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial.
Patel MI, Sundaram V, Desai M, Periyakoil VS, et al · · 2018 · cited 88× · PMID 30054634 · DOI 10.1001/jamaoncol.2018.2446
Long-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial.
Patel MI, Agrawal M, Blayney DW, Bundorf MK, et al · · 2024 · cited 6× · PMID 38814627 · DOI 10.1001/jamaoncol.2024.1221

Verify or expand the search:

Other recruiting trials for End of Life

Currently open trials in the same condition.

NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting
NCT06722352 — Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP) · NA · recruiting
NCT07191184 — Identification of Obstacles and Levers to the Outpatient Care of Patients in Terminal Palliative Situations · recruiting
NCT06071078 — Impact of a Protocol for Announcing Decision of Withholding and Withdrawing Life-sustaining Treatments on the Stress of · NA · recruiting
NCT05861323 — Feasibility of the Comfort Measures Only Time Out (CMOT) · NA · active not recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02966509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 4 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02966509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing